Johnson & Johnson consensus stays supportive, shares trade near 231 dollars

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:20.

Johnson & Johnson (US4781601046) starts this Tuesday with a solid analyst backdrop and a stable New York Stock Exchange quotation around 231 dollars per share, according to price data from NYSE-based providers. The healthcare heavyweight sits in the S&P 500 and remains a core holding in many global portfolios, supported by a long dividend history and double-digit upside in several 12-month target ranges from sell-side houses.

What analysts are pricing in

Consensus data compiled by platforms that track Wall Street research show average 12-month price targets for Johnson & Johnson in a corridor around 252 to 258 dollars per share, implying roughly 9 to 12 percent upside versus the current level of about 231 dollars. Forecast and consensus overview A separate analyst aggregation from Benzinga cites a slightly higher average target of approximately 257.86 dollars, with individual estimates spanning from 250 to 267 dollars per share. Benzinga analyst summary for JNJ

Within this range, some houses maintain neutral ratings, while others position the stock as an outperform idea in large-cap pharmaceuticals and medtech. The consensus framework reflects Johnson & Johnson’s diversified earnings base, its strong balance sheet and its capacity to fund both research and shareholder returns despite a relatively full valuation measured by a mid-20s price-earnings ratio on recent earnings.

Dividend profile and valuation markers

Dividend data from international brokers underline Johnson & Johnson’s role as a classic income stock in the healthcare segment. Recent yield indications cluster around 2.2 to 2.3 percent at a share price near 231 dollars, with an earnings per share figure around 12 dollars and a price-earnings multiple of roughly 27 on current quotations. Broker snapshot on dividend and valuation Independent statistics providers describe the stock as having posted a gain of around 1 to 1.3 percent in the latest trading session, with stability in the low 230-dollar band this week. Recent JNJ price statistics

For institutional and retail investors alike, this combination of dividend continuity and measured target upside places Johnson & Johnson in the camp of lower-volatility healthcare names rather than high-beta biotech shares. The valuation premium versus some peers reflects the perceived resilience of its innovative medicine and medtech franchises after the separation of the consumer business Kenvue in 2023.

How Johnson & Johnson earns its money

Johnson & Johnson today operates with two primary pillars: innovative medicine and medtech, after spinning off its consumer health arm Kenvue in 2023. Business profile and segment description The innovative medicine division focuses on immunology, oncology and neurology therapies, while the medtech business supplies surgical, orthopaedic, vision and interventional solutions to hospitals and clinics worldwide. Together these activities generate well over half of total revenue in the United States, with the remainder spread across Europe, Asia and other regions.

Where the Johnson & Johnson shares trade today

The Johnson & Johnson shares (US4781601046) trade on the NYSE at around 231.29 US dollars as of 2026-06-23, 00:59 EDT, according to broker price data.

This text is for informational purposes only and does not constitute investment advice, investment recommendation or an invitation to buy or sell securities. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.